电话:
400-7060-959
传真:
+86 10 56315212-8813
电子邮件:
orders@antibodies-online.cn

CD20 Protein-VLP (AA 1-297)

MS4A1 宿主: 人 宿主: HEK-293 Cells VLP > 95 % as determined by HPLC Imm, ELISA, Func, SPR Active
产品编号 ABIN7448156
发货至: 中国
  • 抗原 See all CD20 (MS4A1) 蛋白
    CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
    蛋白类型
    VLP
    生物活性
    Active
    产品特性
    AA 1-297
    宿主
    • 22
    • 3
    • 1
    • 1
    资源
    • 11
    • 8
    • 3
    • 2
    • 1
    • 1
    • 1
    HEK-293 Cells
    应用范围
    Immunogen (Imm), ELISA, Functional Studies (Func), Surface Plasmon Resonance (SPR)
    原理
    Human CD20 Protein-VLP
    序列
    Met1-Pro297
    产品特性
    Recombinant Human CD20 Protein-VLP is expressed from HEK293.It contains Met1-Pro297.
    纯度
    > 95 % as determined by HPLC
    过滤
    0.22 μm filtered
    内毒素水平
    Less than 1EU per μg by the LAL method.
    Biological Activity Comment
    Immobilized Human CD20 VLP at 5μg/ml (100μl/Well) on plate on the plate. Dose response curve for Rituximab, hFc Tag with the EC50 of 8.7ng/ml determined by ELISA (QC Test).
    Top Product
    Discover our top product MS4A1 蛋白
  • 应用备注
    • Antibody Discovery: Immunization, Screening, Functional Characterization
    • Affinity determination: ELISA, SPR
    • In vivo pharmacokinetic analysis
    • CMC method development
    • CAR-T Positive Rate Detection
    • Blood sample determination: ELISA
    说明

    Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios.

    Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses.

    Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.

    限制
    仅限研究用
  • 状态
    Liquid
    缓冲液
    Supplied as 0.22μm filtered solution in PBS ( pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.
    储存条件
    -80 °C
    储存方法
    Valid for 12 months from date of receipt when stored at -80°C., Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
    有效期
    12 months
  • 抗原
    CD20 (MS4A1) (Membrane-Spanning 4-Domains, Subfamily A, Member 1 (MS4A1))
    别名
    CD20 (MS4A1 产品)
    别名
    B1 Protein, Bp35 Protein, CD20 Protein, CVID5 Protein, LEU-16 Protein, MS4A2 Protein, S7 Protein, AA960661 Protein, Cd20 Protein, Ly-44 Protein, Ms4a2 Protein, MS4A1 Protein, bp35 Protein, cd20 Protein, ms4a2 Protein, leu-16 Protein, ms4a4c Protein, cd20-like Protein, membrane spanning 4-domains A1 Protein, membrane-spanning 4-domains, subfamily A, member 1 Protein, B-lymphocyte antigen CD20 Protein, MS4A1 Protein, Ms4a1 Protein, ms4a1 Protein, LOC101694281 Protein
    背景
    B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity.CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.
    分子量
    34.3 kDa.
You are here: